Effect of Modified Juanbitang on Inflammatory Factors and Serum MMP-3, OPG and RANKL in Synovial Fluid of Patients with Wind-cold-wetness Type Rheumatoid Arthritis

LI Jian; RONG Bing; JIA Jun; PAN Ming-zhu

doi:10.13422/j.cnki.syfjx.2017220165

您当前的位置：

首页 >

文章列表页 >

Effect of Modified Juanbitang on Inflammatory Factors and Serum MMP-3, OPG and RANKL in Synovial Fluid of Patients with Wind-cold-wetness Type Rheumatoid Arthritis

更新时间：2024-01-04

- Effect of Modified Juanbitang on Inflammatory Factors and Serum MMP-3, OPG and RANKL in Synovial Fluid of Patients with Wind-cold-wetness Type Rheumatoid Arthritis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 22, Pages: 165-170(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017220165
  CLC： R259
- Published：2017
- 稿件说明：
移动端阅览
LI Jian, RONG Bing, JIA Jun, et al. Effect of Modified Juanbitang on Inflammatory Factors and Serum MMP-3, OPG and RANKL in Synovial Fluid of Patients with Wind-cold-wetness Type Rheumatoid Arthritis[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(22): 165-170.
DOI：

LI Jian, RONG Bing, JIA Jun, et al. Effect of Modified Juanbitang on Inflammatory Factors and Serum MMP-3, OPG and RANKL in Synovial Fluid of Patients with Wind-cold-wetness Type Rheumatoid Arthritis[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(22): 165-170. DOI： 10.13422/j.cnki.syfjx.2017220165.

摘要

目的：探讨风寒湿痹型类风湿关节炎（RA）应用蠲痹汤加减治疗的临床效果，及对患者关节液中炎症因子、生活质量的影响。方法：选取天津中医药大学第一附属医院2015年1月—2017年1月收治的134例RA患者，采用随机数字表法均分为两组。两组患者均给予相同的非药物治疗，对照组在此基础上予以美洛昔康+甲氨喋呤治疗，观察组予蠲痹汤加减治疗。比较两组患者中医证候疗效，治疗前后理化指标、关节液炎症因子水平、生活质量评分及血清基质金属蛋白酶-3（matrix metalloproteinase-3，MMP-3），骨保护素（osteoprotegerin，OPG）及核转录因子-κB受体活化因子（receptor activator for nuclear factor-κB ligand，RANKL）表达水平，并观察不良反应。结果：治疗12周后，观察组中医证候疗效有效率为94.0%，对照组为82.1%，观察组优于对照组（P<0.05）。与治疗前比较，两组患者治疗12周后红细胞沉降率（erythrocyte sedimentation tate，ESR）值及血清C反应蛋白（C-reactive protein，CRP），类风湿因子（rheumatoid factor，RF）水平均明显降低（P<0.05），且观察组下降更明显（P<0.05）。两组患者治疗12周后关节液肿瘤坏死因子（tumor necrosis factor，TNF）-α，白细胞介素（interleukin，IL）-17水平均明显低于治疗前（P<0.05），观察组降低更明显（P<0.05）。与治疗前相比，两组患者治疗12周后生理健康总评（physical component summary，PCS），心理健康总评（mental component summary，MCS）评分均明显上升（P<0.05），观察组升高更明显（P<0.05），与治疗前比较，两组患者治疗后 MMP-3及RANKL水平降低，OPG水平升高（P<0.05）。与对照组比较，观察组治疗后RANKL水平明显降低（P<0.05）。结论：风寒湿痹型RA应用蠲痹汤加减治疗更能有效缓解或消除患者的症状体征、减轻机体炎症反应，延缓病情进展，提高生活质量，疗效更优。

Abstract

Objective: To explore the clinical effect of modified Juanbitang on patients with wind-cold-wetness type rheumatoid arthritis (RA) and its effect on inflammatory factors and quality of life. Method: The 134 cases with RA treated at our hospital from January 2015 to January 2017 were selected as research objectives

and randomly divided into two groups. The same nonpharmacological treatment was provided to both groups. The control group was additionally given meloxicam+methotrexate

and the observation group was treated with modified Juanbitang. Two groups' traditional Chinese medicine (TCM) syndrome

physical and chemical indicators before and after treatment

synovial fluid inflammatory factor level

quality of life

serum matrix metalloproteinase-3 (MMP-3)

bone protection element osteoprotegerin (OPG) and receptor activator for nuclear factor-κB ligand (RANKL) expression were recorded and compared. Adverse reactions were also observed. Result: After treatment for 12 weeks

the overall effective rate of TCM syndrome in observation group was 94.0%

which was significantly higher than 82.1% in control group. The observation group was superior to control group. The two group's erythrocyte sedimentation rate erythrocyte sedimentation rate (ESR)

serum C-reactive protein (CRP)

rheumatoid factor (RF) after treatment for 12 weeks were significant lower than those before treatment (P<0.05)

and those in observation group were decreased more significantly (P<0.05). Two groups' joint fluid tumor necrosis factor (TNF)-α

and interleukin interleukin-17 (IL-17) after treatment for 12 weeks were significant lower than those before treatment (P<0.05)

and those in observation group were decreased more significantly (P<0.05). Two groups' physical component summary (PCS) and mental component summary (MCS) after treatment for 12 weeks were significant higher than those before treatment (P<0.05)

and those in observation group were increased more significantly (P<0.05). Compared with before treatment

MMP-3 and RANKL levels of two groups reduced

while OPG increased after treatment (P<0.05). Compared with control group

RANKL level of treatment group was significantly decreased after treatment

with statistically significant differences (P<0.05). Conclusion: Modified Juanbitang can relieve or eliminate the symptoms and signs of patients with wind-cold-wetness type RA

reduce the systemic inflammatory response

delay the disease progression

and improve the life quality

with a good clinical effect.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Duanteng Yimu Decoction on Expression of MEKK2 in Rheumatoid Arthritis Synovial Fibroblasts and Arthritis in CIA Mice

Protective Effect against Helicobacter pylor Gastritis in Mice by Flavonoid Combinations of Alpiniae Officinarum Rhizoma via Inhibition of PI3K/Akt Pathway

Protective Effect of Taohong Siwutang on Cerebral Ischemia-reperfusion Injury Based on A1/A2 Phenotype Transformation of Astrocytes Mediated by JAK2/STAT3 Pathway

Editorial Explanation of Guidelines for Establishing Animal Models of Rheumatoid Arthritis with Cold-dampness Obstruction Syndrome and Dampness-heat Obstruction Syndrome

Guidelines for Establishing Animal Models of Rheumatoid Arthritis with Cold-dampness Obstruction Syndrome and Dampness-heat Obstruction Syndrome

Related Author

Qiang WANG

Long-yin HAN

Zhen-quan WEI

Nan LI

Dong-mei PAN

Min-ying LIU

Chang-song LIN

LUO Xin

Related Institution

First College of Clinical Medicine, Guangzhou University of Chinese Medicine

School of Traditional Chinese Medicine(TCM), Jinan University

School of TCM, Southern Medical University

The First Affiliated Hospital, Guangzhou University of Chinese Medicine

Hubei Key Laboratory of Resource and Chemistry of Chinese Medicine，School of Pharmacy， Hubei University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰